PanGen Biotech Inc. (KOSDAQ:222110)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,995.00
+25.00 (0.50%)
At close: Sep 4, 2026

PanGen Biotech Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
1,1322,051943.69-4,489-4,494-3,310
Depreciation & Amortization
1,5331,4651,4681,5971,6031,532
Loss (Gain) From Sale of Assets
0.86-17.01-13.94-15.150.240.67
Stock-Based Compensation
---12.18236.78224.6
Provision & Write-off of Bad Debts
-214.44-252.64148.57148.57--
Other Operating Activities
52.3-78.92658.721,052642.78693.36
Change in Accounts Receivable
-687.661,646-746.76-1,659386.46-552.25
Change in Inventory
-974.18-1,228930.24-752.12-2,257-608.69
Change in Accounts Payable
146.52-265.49124.5143.34-126.4385.41
Change in Other Net Operating Assets
-3,549-3,130-526.46612.11505.41-1,389
Operating Cash Flow
-2,561189.812,987-3,451-3,503-3,324
Operating Cash Flow Growth
--93.64%----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-878.49-562.81-360.06-422.13-728.05-1,425
Sale of Property, Plant & Equipment
-017.0915015.234.62-
Sale (Purchase) of Intangibles
-190.52-174.61-14.07-62.86-5.8-49.29
Investment in Securities
-854.7250.3-10,077-5015,048-4,451
Other Investing Activities
-433.18-342.16-35.8-51.34-119.4-100.22
Investing Cash Flow
-2,357-812.18-10,337-571.1314,229-6,026

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
--980986--
Long-Term Debt Issued
---3,20460.1968.91
Total Debt Issued
--9804,19060.1968.91
Short-Term Debt Repaid
---980-986--
Long-Term Debt Repaid
--1.84-516.88-1.56-18,829-1.04
Total Debt Repaid
-1,063-1.84-1,497-987.56-18,829-1.04
Net Debt Issued (Repaid)
-1,063-1.84-516.883,202-18,76967.88
Issuance of Common Stock
-2,9679,261-33.6810,051
Other Financing Activities
-0.41-2.69-9.43-27.34-0.51-6.16
Financing Cash Flow
-1,0642,9638,7353,175-18,73610,112

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-12.59-14.86----
Miscellaneous Cash Flow Adjustments
0----0-0
Net Cash Flow
-5,9942,3261,385-847.06-8,009762.18

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-3,440-3732,627-3,873-4,231-4,749
Free Cash Flow Growth
------
Free Cash Flow Margin
-24.26%-2.78%17.90%-52.94%-65.08%-59.85%
Free Cash Flow Per Share
-253.26-27.69228.26-362.36-396.34-464.83
Levered Free Cash Flow
-1,8181,280228.45-1,012-2,828-4,331
Unlevered Free Cash Flow
-1,7401,372429.76-874.1-2,748-4,148

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
0.290.121.152.290.530.53
Cash Income Tax Paid
-60.9169.84-39.5179.3934.79
Change in Working Capital
-5,065-2,978-218.46-1,756-1,492-2,464